• Moderna Stock Offering Is to Price at $76 Per Share

    Moderna Stock Offering Is to Price at $76 Per Share(Bloomberg) — Moderna Inc. plans to raise as much as $1.3 billion through a sale of shares to fund manufacturing of a coronavirus vaccine seen as one of the frontrunners in the race for immunization against the widening pandemic. The U.S. biotechnology firm will sell 17.6 million shares priced at $76 a piece, according to a statement Tuesday. The price represents a 5% discount to Monday’s closing price.Morgan Stanley is the sole book-running manager for the offering that allows underwriters to buy an additional 2.64 million shares, the statement said. Bloomberg reported the share sale plan earlier.Shares jumped 20% on Monday after the company revealed positive early results from its experimental vaccine for Covid-19, capping off a 309% rally this year.Moderna’s vaccine is seen as one of the most promising candidates for immunization against the pathogen that has sickened over 4.8 million people worldwide and killed over 318,000 since it first emerged in China last December. A successful vaccine is a crucial step toward lifting lockdowns, easing social distancing measures and safely reopening economies gutted by strict containment efforts. The promising results that Moderna reported were just a sample from the small, first study designed to look at the safety of the shot in human volunteers. But they showed no major safety worries – a key first hurdle since a vaccine would be given to millions of otherwise healthy people.“This is a very good sign that we make an antibody that can stop the virus from replicating,” Moderna Chief Executive Officer Stephane Bancel said in an interview Monday. The data “couldn’t have been better.”The biotech firm is moving ahead with plans for a larger test to pick a dose of the vaccine and further study its effectiveness, as well as a phase 3 test that will administer the vaccine to many thousands of patients.The safety profile appeared to be good, Bancel said, and the reactions were typical of vaccines. Three patients who got a high dose of the vaccine had more severe side effects, according to a company presentation. That dose won’t be used in later trials.Side effects seen in the trial included fatigue, fever, muscle pains and headache but all the symptoms resolved within a day.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

    from Yahoo Finance https://ift.tt/36c0haJ

  • The ASX big bank stock most likely to outperform in the COVID-19 recovery

    big four banks

    The S&P/ASX 200 Index (Index:^AXJO) is surging higher on encouraging news of a possible vaccine for COVID-19 and comments from US Federal Reserve head Jerome Powell on more stimulus.

    It seems the Fed is not running out of juice to liquor-up financial markets, while Boston-based biotech Moderna announced better than expected early trial results.

    If the bulls are right about the worst being over, it will have implications for the performance of the big four ASX banks.

    Passing the baton

    During the meltdown, it’s the Commonwealth Bank of Australia (ASX: CBA) share price that held up better than its peers. That’s understandable as investors are willing to cough up a premium during a crisis to hold the highest quality and safest domestic bank.

    But if animal spirits are running wild, the tide will turn. Investors will be more aggressively turning to value buys and this means beloved CBA is likely to be left behind in the rebound.

    The question then is which of the other three big banks will take the crown? There isn’t much difference in valuations of Australia and New Zealand Banking GrpLtd (ASX: ANZ), Westpac Banking Corp (ASX: WBC) and National Australia Bank Ltd. (ASX:NAB).

    Best bank for the COVID-19 rebound

    But NAB seems to be a hot favourite among some leading brokers. For instance, Goldman Sachs put the stock in its “conviction” buy list as NAB is its top pick in the sector.

    The broker is bullish on the bank due to its dramatic improvement in operational performance in recent years and it sees better revenue potential given NAB’s bigger exposure to small and medium sized business lending.

    Meanwhile, JP Morgan is also backing NAB in the four-horse race. While the bank reported a disappointing first half profit result recently, the broker believes it displayed the most resilient top-line if you excluded the bank’s underperforming Markets division.

    Don’t discount CBA just yet

    Coincidentally, both brokers rate CBA a “sell” due to its lofty valuation. I own shares in all the big four banks but remain overweight on CBA as I don’t believe we have seen the last of the coronavirus volatility.

    Let’s not forget that CBA also continues to win market share for home loans despite its dominance in the sector.

    Just as importantly, my experience tells me that its seldom premium valuations that really hurt my share portfolio performance. The real culprits are balance sheet and governance issues – factors that weigh more heavily on the other three.

    Buy into NAB’s SPP

    But I agree that NAB is likely to pull ahead of its peers if the skies are as blue as it appears today. If you share my belief that we have seen the worst of the coronavirus market meltdown and are happy to stomach the volatility, NAB looks enticing.

    This is why I plan to participate in NAB’s share purchase plan, which closes this Friday. I doubt you can buy NAB shares lower than the $14.15 a share offer price again for a long time.

    Just remember not to put all your eggs into one basket. It’s better to hold a few bank stocks for diversification.

    But ASX bank stocks aren’t the only shares to bank on in a recovery…

    UPDATED: Free report names 5 “bounce back” stocks for building wealth

    It’s painful watching your wealth disintegrate before your eyes.

    But what can be even more painful is missing out on what could be an inevitable bounce back for the stock market.

    Master investor Scott Phillips has sifted through the wreckage and identified the 5 stocks he thinks could bounce back the hardest once the coronavirus is contained.

    The report is called 5 Stocks For Building Wealth after 50, and you can grab a copy for FREE for a limited time only.

    But you will have to hurry — history has shown the market could bounce significantly higher before the virus is contained, meaning the cheap prices on offer today might not last for long.

    Click Here

    More reading

    Motley Fool contributor Brendon Lau owns shares of Australia & New Zealand Banking Group Limited, Commonwealth Bank of Australia, National Australia Bank Limited, and Westpac Banking. Connect with me on Twitter @brenlau.

    The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post The ASX big bank stock most likely to outperform in the COVID-19 recovery appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/2z9VyKK

  • 3 Warren Buffett ASX dividend shares to buy right now

    warren buffett

    I think Warren Buffett is one of the world’s best investors. Berkshire Hathaway doesn’t pay a dividend, but he likes to invest in shares that do pay a dividend. I think there are some ASX dividend shares that could be worth buying.

    Here are some great income ideas that could be worth buying during these coronavirus times:

    Washington H. Soul Pattinson and Co. Ltd (ASX: SOL) 

    Soul Patts is often described as the Australian version of Berkshire Hathaway. It invests in both listed and unlisted businesses & assets.

    Some of the ASX shares that it’s invested in include TPG Telecom Ltd (ASX: TPM), Brickworks Limited (ASX: BKW) and Clover Corporation Limited (ASX: CLV). Some of its unlisted investments include swim schools and agriculture.

    Warren Buffett’s preferred holding period for shares is forever. I think Soul Patts is well placed to keep growing for decades to come and it has already been around for over 100 years.

    As a bonus it has a grossed-up dividend yield of 4.7%. This dividend has increased every year since 2000. The dividend is purely funded by the investment income it receives, less expenses.

    APA Group (ASX: APA) 

    APA Group is an ASX energy infrastructure giant. I think Warren Buffett would really like this share because Berkshire Hathaway Energy is one of the US business’ biggest divisions.

    It owns a vast network of 15,000km of natural gas pipelines around Australia with a presence in every mainland state and the Northern Territory. It also owns or has interests in gas storage facilities, gas-fired power stations and renewable energy generation (wind and solar farms). APA owns, or manages and operates, a portfolio of assets worth more than $21 billion and delivers half the nation’s natural gas usage.

    APA is actually looking for opportunities in the US which would be a good way to strengthen and diversify earnings further.

    The energy giant currently offers a distribution yield of 4.4%.

    Duxton Water Ltd (ASX: D2O) 

    I think Warren Buffett’s share choices and his previous comments show he likes investing in businesses that are ‘essential’ for western life like Apple, energy and insurance.

    Water is an integral part of the agriculture process for farmers. Duxton Water provides access to water entitlements which can either be leased for multiple years or it can provide short-term access.

    The amount of water that is now leased means Duxton Water’s board has been confident enough to project growing dividends for the next two years.

    I calculate that based on the next 12 months of dividends the forward grossed-up dividend yield is 6.25%.

    Which Warren Buffett ASX dividend share is best?

    I think APA looks fairly priced now, so I wouldn’t call it a buy. Soul Patts is the one with the best dividend record and I believe it’s the one that’s most like Berkshire Hathaway. So Soul Patts would be the one I’d go for as a Warren Buffett ASX dividend share.

    But these three aren’t the only great dividend share ideas to consider buying.

    NEW: Expert names top dividend stock for 2020 (free report)

    When our resident dividend expert Edward Vesely has a stock tip, it can pay to listen. After all, he’s the investing genius that runs Motley Fool Dividend Investor, the newsletter service that has picked huge winners like Dicker Data (+92%), SDI Limited (+53%) and National Storage (+35%).*

    Edward has just named what he believes is the number one ASX dividend stock to buy for 2020.

    This fully franked “under the radar” company is currently trading more than 24% below its all-time high and paying a 6.7% grossed-up dividend.

    The name of this dividend dynamo and the full investment case is revealed in this brand new free report.

    But you will have to hurry — history has shown it can pay dividends to get in early to some of Edward’s stock picks, and this dividend stock is already on the move.

    See the top dividend stock for 2020

    More reading

    Tristan Harrison owns shares of DUXTON FPO and Washington H. Soul Pattinson and Company Limited. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Clover Limited. The Motley Fool Australia owns shares of and has recommended Brickworks and Washington H. Soul Pattinson and Company Limited. The Motley Fool Australia owns shares of APA Group. The Motley Fool Australia has recommended DUXTON FPO. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post 3 Warren Buffett ASX dividend shares to buy right now appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/3g8qMTl

  • PFE | Pfizer and German Parker BioNTech SE have begun delivering doses of their coronavirus vaccine for human testing US, trials in Germany already underway.

  • The performance outlook of tech companies.

  • Top broker urging you to buy this ASX 200 retail stock next week